Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with $0.01 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 101.23% year-over-year to $0.01, compared with a TTM value of -$2.16 through Sep 2025, down 300.0%, and an annual FY2024 reading of $0.87, up 103.59% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.01 for Q3 2025 at Kiora Pharmaceuticals, up from -$0.54 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.46 in Q1 2024 and bottomed at -$22.89 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.03, with a median of -$0.74 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 14642.81% in 2022, then soared 446.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$21.43 in 2021, then skyrocketed by 65.61% to -$7.37 in 2022, then surged by 87.79% to -$0.9 in 2023, then decreased by 23.33% to -$1.11 in 2024, then soared by 100.9% to $0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KPRX at $0.01 in Q3 2025, -$0.54 in Q2 2025, and -$0.52 in Q1 2025.